PMID- 29643001
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20230314
IS  - 0028-3843 (Print)
IS  - 0028-3843 (Linking)
VI  - 52
IP  - 4
DP  - 2018 Aug
TI  - Immune-cell BDNF expression in treatment-naive relapsing-remitting multiple 
      sclerosis patients and following one year of immunomodulation therapy.
PG  - 483-489
LID - S0028-3843(18)30083-5 [pii]
LID - 10.1016/j.pjnns.2018.03.006 [doi]
AB  - Although neurons are the main source of neurotrophins in the healthy brain, 
      neurotrophins can also be expressed in the immune system. We have previously 
      shown that in relapsing-remitting multiple sclerosis (RRMS) lower immune-cell 
      neurotrophin levels are associated with brain atrophy and cognitive impairment. 
      The aim of the present study was to assess if immune-cell neurotrophin expression 
      is impaired in MS as compared with the healthy controls, and to describe if these 
      levels change in treatment-naive RRMS patients, following one year of 
      immunomodulation. Fifty treatment-naive RRMS patients were assessed at baseline 
      and after one year of immunomodulation (beta-interferons/glatiramer acetate). The 
      control group included 39 healthy subjects matched according to age and gender. 
      Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood 
      using Ficoll-Histopaque gradient. The levels of brain-derived-neurotrophic-factor 
      (BDNF), beta-nerve-growth-factor (beta-NGF), neurotrophin-3 (NT-3) and 
      neurotrophin-4/5 (NT-4/5) were measured in PBMC lysates with ELISA. BDNF levels 
      were significantly lower in MS than in the healthy controls (median 613 vs. 
      1657pg/mg protein, p<0.001). After one year of immunomodulation, BDNF expression 
      did not change significantly (p=0.06) on the group level. In 70% of patients 
      there was no increase in BDNF level, and in 30% it increased. We observed no 
      differences between treatment groups. Other neurotrophins were detected in a 
      minority of MS samples (as opposed to the controls). To conclude, we have shown 
      that immune-cell production of neurotrophins is impaired in MS patients. In our 
      MS cohort standard immunomodulation failed to restore normal BDNF levels in PBMCs 
      within one year of therapy.
CI  - Copyright (c) 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. 
      All rights reserved.
FAU - Kalinowska-Lyszczarz, Alicja
AU  - Kalinowska-Lyszczarz A
AD  - Division of Neurochemistry and Neuropathology, Department of Neurology, Poznan 
      University of Medical Sciences (PUMS), 49 Przybyszewskiego Street, 60-355 Poznan, 
      Poland. Electronic address: akalinowskalyszczarz@ump.edu.pl.
FAU - Pawlak, Mikolaj A
AU  - Pawlak MA
AD  - Department of Neurology and Cerebrovascular Disorders, Poznan University of 
      Medical Sciences, 34 Dojazd Street, 60-631 Poznan, Poland. Electronic address: 
      mpawlak@ump.edu.pl.
FAU - Wyciszkiewicz, Aleksandra
AU  - Wyciszkiewicz A
AD  - Division of Neurochemistry and Neuropathology, Department of Neurology, Poznan 
      University of Medical Sciences (PUMS), 49 Przybyszewskiego Street, 60-355 Poznan, 
      Poland. Electronic address: aleksandra.wyciszkiewicz@gmail.com.
FAU - Osztynowicz, Krystyna
AU  - Osztynowicz K
AD  - Division of Neurochemistry and Neuropathology, Department of Neurology, Poznan 
      University of Medical Sciences (PUMS), 49 Przybyszewskiego Street, 60-355 Poznan, 
      Poland. Electronic address: osztynowiczkr@ump.edu.pl.
FAU - Kozubski, Wojciech
AU  - Kozubski W
AD  - Department of Neurology, Poznan University of Medical Sciences, 49 
      Przybyszewskiego Street, 60-355 Poznan, Poland. Electronic address: 
      wkozubski@ump.edu.pl.
FAU - Michalak, Slawomir
AU  - Michalak S
AD  - Division of Neurochemistry and Neuropathology, Department of Neurology, Poznan 
      University of Medical Sciences (PUMS), 49 Przybyszewskiego Street, 60-355 Poznan, 
      Poland. Electronic address: slamic@yahoo.com.
LA  - eng
GR  - R01 AG013743/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20180329
PL  - Poland
TA  - Neurol Neurochir Pol
JT  - Neurologia i neurochirurgia polska
JID - 0101265
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
SB  - IM
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Humans
MH  - Immunomodulation
MH  - Leukocytes, Mononuclear
MH  - *Multiple Sclerosis, Relapsing-Remitting/metabolism
MH  - Nerve Growth Factors
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor (BDNF)
OT  - Immunomodulation
OT  - Neurotrophic factors
OT  - Neurotrophins
OT  - Relapsing-remitting multiple sclerosis (RRMS)
EDAT- 2018/04/13 06:00
MHDA- 2019/05/24 06:00
CRDT- 2018/04/13 06:00
PHST- 2018/02/22 00:00 [received]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/04/13 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2018/04/13 06:00 [entrez]
AID - S0028-3843(18)30083-5 [pii]
AID - 10.1016/j.pjnns.2018.03.006 [doi]
PST - ppublish
SO  - Neurol Neurochir Pol. 2018 Aug;52(4):483-489. doi: 10.1016/j.pjnns.2018.03.006. 
      Epub 2018 Mar 29.